We are proud to announce the geko device has secured NHS Supply Chain (NHSSC) listing on the Advanced Wound Care framework—a significant milestone that enhances access to the geko device across the UK. “The listing is more than a procurement achievement—it is recognition of the geko...
We are proud to announce a major new distribution partnership with BIOS Strategic Partners (BIOS SP) — a recognized leader in breakthrough medical technology distribution. Under this new collaboration, BIOS SP will introduce the geko® device T3 and W3 to over 40 Veterans Affairs (VA) medical...
We have been honoured with a prestigious King's Award for Enterprise in Innovation. As part of the honour, Mark Whalley, VP of Operations - representing our company - attended a special reception hosted by King Charles III at Windsor Castle, celebrating the winners of this...
I am incredibly proud to share that Sky Medical Technology has been awarded the King’s Award for Enterprise in Innovation. This is a significant moment for our team, and one that reflects years of dedicated work across research, development, and clinical application. At the heart of...
Sky Medical Technology has welcomed the news that its geko device, an innovative neuromuscular electrostimulator, has received regulatory approval for use in China. This marks a significant milestone for the company and represents a major growth opportunity in one of the world’s largest and most...
Sky Medical Technology has welcomed the news that The Canadian Home Care Association (CHCA) is endorsing the Canadian Consensus Statement on the Treatment of Venous Leg Ulcers, a guideline designed to improve patient outcomes through standardised, evidence-based care. Aligning with CHCA's mission to enhance quality and...
High-quality evidence to guide treatment selection of chronic wound healing remains lacking. The conventional parallel-arm randomized controlled trial (RCT) model for wound healing studies has limitations. Complete wound closure as a primary endpoint necessitates trials with large sample sizes and prolonged follow-up to achieve adequate...
We are pleased to share that the geko device is now reimbursed in the UK, enabling clinicians to make a recommendation to the relevant approval committee within their local Integrated Care System (ICS) that the device should be considered for local formulary inclusion. In turn, reimbursement...
The NHS spends almost as much on hard-to-heal chronic wounds every year (£5.3 billion) as on cancer treatment (£5.6 billion). However, poor patient adherence to current standard of care has led to 15 - 20 percent of long-term chronic wounds remaining unhealed after a year,...